Contracting Expansion: A Path to Better CAR T-Cell Therapy Production
Shorter cell expansion steps could significantly accelerate CAR T-cell therapy production processes, according to researchers, who cite microfluidic culture systems, real-time PAT tools, and AI-enabled predictive models as key enablers of this new rapid manufacturing paradigm. The post Contracting Expansion: A Path to Better CAR T-Cell Therapy Production appeared first on GEN - Genetic…
Reducing the duration of cell expansion in CAR T-cell therapy production could lead to more potent, lower-dose products reaching patients faster than those made through existing methods. While the process of creating a CAR T-cell therapy—from separation to cryopreservation—typically takes between 10 to 21 days, this wait period can be too long for critically ill patients.
In 2024, it was estimated that around 30% of therapies produced annually remain unused due to the recipient's health decline during the production process. Consequently, improving "vein-to-vein time" or the time required to transform patient-derived material into a therapy and administer it, has become a priority for the CAR T industry.
Most initiatives are centered around enhancing process efficiency or decentralized production. An alternative approach to decrease vein-to-vein times involves shortening ex vivo expansion, according to Marta Costa, PhD, and her team at Portugal’s iBET. A rapid manufacturing strategy would yield more effective and consistent therapies by limiting expansion to three days or less.
This approach preserves naïve and stem cell-like memory T cells, which proliferate and persist better post-infusion, potentially resulting in lower CAR T cell doses. Costa emphasizes that achieving this precise control over production processes will necessitate innovative digital technologies. Automated systems, like the CliniMACS Prodigy and Lonza’s Cocoon, can expedite production by integrating various steps in a closed system, ensuring product quality.
However, faster analytics for product release are also essential, as several assays currently take a week or more to assess safety and potency. Additionally, artificial intelligence modeling could play a significant role. By predicting how cells will grow and differentiate and continuously monitoring cell state, AI can dynamically adjust process parameters and optimize harvest timepoints based on evolving cell states rather than a predetermined culture duration.
Costa concludes that the increasing evidence suggests that cell quality outweighs cell quantity. Shorter production processes generate fitter cells, reduce costs, boost capacity, and benefit patients unable to wait weeks. This combination, along with the rising momentum behind in vivo CAR T cell strategies that eliminate ex vivo manufacturing, offers promising prospects for the future of CAR T-cell therapy production.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
